<DOC>
	<DOCNO>NCT02591836</DOCNO>
	<brief_summary>The primary purpose placebo-controlled study evaluate low‐density lipoprotein cholesterol ( LDL‐C ) efficacy dose‐response gemcabene 300 , 600 900 mg/day administer monotherapy combination atorvastatin 10 , 40 , 80 mg/day hypercholesterolemic patient . Secondary purpose include evaluate effect high‐sensitivity C-reactive protein ( hsCRP ) , high‐density lipoprotein cholesterol ( HDL‐C ) , triglyceride ( TG ) apolipoprotein B ( ApoB ) , safety efficacy gemcabene monotherapy gemcabene/atorvastatin combination .</brief_summary>
	<brief_title>Efficacy Safety Gemcabene Hypercholesterolemic Patients Monotherapy Combination With Atorvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Males Females 18‐70 year old Received statin monotherapy LDL‐C &gt; 100 mg d/L initial clinical washout visit OR Received lipid‐altering drug since initial clinic washout visit mean LDL‐C follow 2 qualify visit : ≥ 130 mg/dL National Cholesterol Education Program ( NCEP ) Adult Treatment Panel III ( ATP III ) Coronary Heard Disease ( CHD ) risk ≥ 10 % ; OR ≥ 160 mg/dL NCEP ATP III CHD risk &lt; 10 % Had variability 2 qualify LDL‐C &lt; 20 % ( i.e . low value/highest value &gt; 0.8 ) . An additional qualifying visit may complete patient wash lipid medication order reassess LDL‐C variability ; Had mean LDL‐C &lt; 250 mg/dL 2 qualify visit Women childbearing potential , pregnant lactating ; Body Mass Index ( BMI ) &gt; 38kg/m² ; TG &gt; 400 mg/dL Visit B2 B3 Unexplained creatinine phosphokinase ( CPK ) &gt; 3 x Upper Limit Normal ( ULN ) history unexplained myopathy ( include rhabdomyolysis ) ; Documented cardiac history : Myocardial infarction* , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , symptomatic carotid artery disease peripheral artery disease , ventricular arrhythmia , recurrent supraventricular tachycardia , abnormal QTC interval ( QT correct &gt; 0.44 sec ) , heart failure major cardiovascular event result hospitalization Uncontrolled hypertension* Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus ( HbA1c &gt; 8 % ) diabetic patient take insulin and/or thiazolidinediones Renal dysfunction include chronic renal failure insufficiency , creatinine &gt; 2.0 mg/dL ; Hepatic dysfunction Uncontrolled hypothyroidism Abnormal urinalysis Currently take follow medication : Potent CYP3A4 inhibitor include indinavir , nelfinavir , ritonavir , saquinavir , amiodarone , cimetidine , clarithromycin , erythromycin , erythromycin , fluoxetine , itraconazole , ketoconazole , nefazodone troleandomycin well grapefruit juice ; Thiazolidinediones ( Avandia , Actos ) ; Immunosuppressive agent ; St. John 's wort Taking follow lipid‐altering medication within 5 week prior randomization : Lipid‐regulating drug : Niacin ( crystalline &gt; 500mg/day , slow release time release ) , psyllium preparation Metamucil ( &gt; 2 tablespoons/day ) , fibrates derivative , bile cholesterol absorption inhibitor include ezetimibe ; Any supplement containing plan sterols/stanols ( i.e . Benecol , beta‐sitosterol , Cholestatin , Phytoquest , Take Control ) cholestin ( i.e . Chinese red yeast , fermented rice ; Hong Qu , Hong Chu , Herbvalin , Ruby Monascus , Monascus purpureus rice ) ; Neomycin ( oral ) ; Adrenocortical steroids* Sibutramine ( Meridia ) ; Insulin ; Orlistat ( Xenical ) ; Isotretinoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>LDL‐C</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>